Genetic determinants of hyperhomocysteinemia in atherosclerosis

Farah F Eghlim1, Tester F Ashavaid, Kappiareth G Nair

  • 1Research laboratory, P. D. Hinduja National Hospital & Medical Research Center, 400 016 Mumbai, India.

Insights

High homocysteine (Hhcy) levels are linked to atherosclerosis, potentially via inflammation and oxidative stress. This study found associations with specific gene mutations and elevated hs-CRP, supporting Hhcy

Area of Science:

  • Cardiovascular Genetics
  • Biochemistry
  • Molecular Biology

Background:

  • Hyperhomocysteinemia (Hhcy) is an established risk factor for atherosclerosis.
  • Potential mechanisms include inflammation, endoplasmic reticulum (ER) stress, and oxidative stress.

Purpose of the Study:

  • Investigate gene mutations causing Hhcy.
  • Assess inflammatory markers (hs-CRP) and total antioxidant levels.
  • Determine Hcy-dependent gene expression in vivo.

Main Methods:

  • Genotyping for MTHFR, CBS, MS, and eNOS genes using PCR-based restriction enzyme analysis.
  • Gene expression analysis via Reverse Transcriptase PCR and cloning.
  • Measurement of hs-CRP and Total Antioxidant Status (TAS).

Main Results:

  • Significant association found between Hhcy and MTHFR (C677T) and MS (A2756G) genotypes.
  • No association of Hhcy with eNOS genotype.
  • Elevated hs-CRP levels and increased manganese superoxide dismutase (Mn SOD) mRNA expression in HHcy patients.
  • Lower TAS levels observed in HHcy patients.
  • No significant change in CD18 gene expression, and no GRP78 gene expression in HHcy lymphocytes.

Conclusions:

  • Hhcy is associated with specific genetic mutations and induces an inflammatory response, evidenced by elevated hs-CRP.
  • Hhcy significantly contributes to oxidative stress, indicated by lower TAS and higher Mn SOD expression.
  • These factors collectively promote vascular damage and atherosclerosis development.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...